MedTrace Logo

An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia

NCT00487591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2008-05-07

No results posted yet for this study

Summary

The primary objective of this study is to compare the effect of simvastatin plus Omacor to simvastatin plus placebo for lowering non-high density lipoprotein cholesterol in subjects with mixed dyslipidemia.

Conditions

  • Mixed Dyslipidemia

Interventions

DRUG

Omacor (omega-3-acid ethyl esters)plus simvastatin

Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)

DRUG

simvastatin plus placebo

simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo

Sponsors & Collaborators

  • Reliant Pharmaceuticals

    collaborator INDUSTRY

  • Provident Clinical Research

    lead OTHER

Principal Investigators

  • Kevin C Maki, PhD · Provident Clinical Research

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-08-31
Completion
2007-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487591 on ClinicalTrials.gov